Actinogen Medical Ltd Cash Flow Conversion Efficiency
Actinogen Medical Ltd cash flow conversion efficiency. Based on the latest financial reports, Actinogen Medical Ltd (ACW) has a cash flow conversion efficiency ratio of -0.507x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-9.29 Million ≈ $-6.58 Million USD) by net assets (AU$18.34 Million ≈ $12.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Actinogen Medical Ltd (2008–2025)
Cash flow conversion efficiency of Actinogen Medical Ltd from 2008 to 2025. This chart illustrates how Actinogen Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Actinogen Medical Ltd stock quote for real-time trading data and today's change.
Actinogen Medical Ltd Cash Flow Conversion Ratio Explained
Actinogen Medical Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Actinogen Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinogen Medical Ltd ranked by their cash flow conversion efficiency. Also see Actinogen Medical Ltd (ACW) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China New Higher Education Group Limited
F:8CN
|
0.040x |
|
Electrotherm (India) Limited
NSE:ELECTHERM
|
-1.082x |
|
Nicola Mining Inc
V:NIM
|
0.542x |
|
Charnic Capital Tbk PT
JK:NICK
|
-0.044x |
|
Shinhung
KO:004080
|
-0.009x |
|
Hexa Tradex Limited
NSE:HEXATRADEX
|
0.000x |
|
Sitowise Group Oyj
HE:SITOWS
|
0.162x |
|
SynAct Pharma AB
ST:SYNACT
|
-0.170x |
Annual Cash Flow Conversion Efficiency for Actinogen Medical Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Actinogen Medical Ltd from 2008 to 2025. Review ACW cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$18.34 Million ≈ $12.97 Million |
AU$-7.56 Million ≈ $-5.35 Million |
-0.412x | +52.12% |
| 2024-06-30 | AU$19.70 Million ≈ $13.94 Million |
AU$-16.95 Million ≈ $-11.99 Million |
-0.861x | -32.65% |
| 2023-06-30 | AU$13.41 Million ≈ $9.49 Million |
AU$-8.70 Million ≈ $-6.15 Million |
-0.649x | -48.20% |
| 2022-06-30 | AU$21.74 Million ≈ $15.38 Million |
AU$-9.52 Million ≈ $-6.73 Million |
-0.438x | -343.34% |
| 2021-06-30 | AU$17.46 Million ≈ $12.35 Million |
AU$-1.72 Million ≈ $-1.22 Million |
-0.099x | +62.35% |
| 2020-06-30 | AU$10.89 Million ≈ $7.70 Million |
AU$-2.86 Million ≈ $-2.02 Million |
-0.262x | +60.87% |
| 2019-06-30 | AU$15.66 Million ≈ $11.08 Million |
AU$-10.50 Million ≈ $-7.43 Million |
-0.670x | -46.20% |
| 2018-06-30 | AU$17.26 Million ≈ $12.21 Million |
AU$-7.91 Million ≈ $-5.60 Million |
-0.458x | -287.20% |
| 2017-06-30 | AU$9.37 Million ≈ $6.63 Million |
AU$-1.11 Million ≈ $-784.55K |
-0.118x | +71.51% |
| 2016-06-30 | AU$12.13 Million ≈ $8.58 Million |
AU$-5.04 Million ≈ $-3.57 Million |
-0.416x | -71.57% |
| 2015-06-30 | AU$15.36 Million ≈ $10.87 Million |
AU$-3.72 Million ≈ $-2.63 Million |
-0.242x | +32.96% |
| 2014-06-30 | AU$1.21 Million ≈ $857.43K |
AU$-437.84K ≈ $-309.80K |
-0.361x | +44.08% |
| 2013-06-30 | AU$194.35K ≈ $137.52K |
AU$-125.56K ≈ $-88.85K |
-0.646x | +72.79% |
| 2012-06-30 | AU$346.99K ≈ $245.52K |
AU$-823.94K ≈ $-582.99K |
-2.375x | -208.31% |
| 2011-06-30 | AU$1.05 Million ≈ $740.20K |
AU$-805.70K ≈ $-570.09K |
-0.770x | -23.70% |
| 2010-06-30 | AU$1.17 Million ≈ $826.62K |
AU$-727.37K ≈ $-514.66K |
-0.623x | -116.57% |
| 2009-06-30 | AU$1.90 Million ≈ $1.35 Million |
AU$-546.87K ≈ $-386.95K |
-0.287x | -106.93% |
| 2008-06-30 | AU$2.86 Million ≈ $2.02 Million |
AU$-397.22K ≈ $-281.06K |
-0.139x | -- |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more